CL2018000057A1 - Composiciones farmacéuticas que comprenden un antagonista de la integrina alfa4 para uso en el tratamiento de afecciones inflamatorias oculares - Google Patents

Composiciones farmacéuticas que comprenden un antagonista de la integrina alfa4 para uso en el tratamiento de afecciones inflamatorias oculares

Info

Publication number
CL2018000057A1
CL2018000057A1 CL2018000057A CL2018000057A CL2018000057A1 CL 2018000057 A1 CL2018000057 A1 CL 2018000057A1 CL 2018000057 A CL2018000057 A CL 2018000057A CL 2018000057 A CL2018000057 A CL 2018000057A CL 2018000057 A1 CL2018000057 A1 CL 2018000057A1
Authority
CL
Chile
Prior art keywords
treatment
pharmaceutical compositions
inflammatory conditions
integrin antagonist
ocular inflammatory
Prior art date
Application number
CL2018000057A
Other languages
English (en)
Spanish (es)
Inventor
Achim Hans-Peter Krauss
Original Assignee
Axerovision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axerovision Inc filed Critical Axerovision Inc
Publication of CL2018000057A1 publication Critical patent/CL2018000057A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CL2018000057A 2015-07-08 2018-01-08 Composiciones farmacéuticas que comprenden un antagonista de la integrina alfa4 para uso en el tratamiento de afecciones inflamatorias oculares CL2018000057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08

Publications (1)

Publication Number Publication Date
CL2018000057A1 true CL2018000057A1 (es) 2018-06-22

Family

ID=56373100

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000057A CL2018000057A1 (es) 2015-07-08 2018-01-08 Composiciones farmacéuticas que comprenden un antagonista de la integrina alfa4 para uso en el tratamiento de afecciones inflamatorias oculares

Country Status (21)

Country Link
US (3) US10413535B2 (cg-RX-API-DMAC7.html)
EP (1) EP3319639B1 (cg-RX-API-DMAC7.html)
JP (2) JP6752276B2 (cg-RX-API-DMAC7.html)
KR (2) KR102440162B1 (cg-RX-API-DMAC7.html)
CN (1) CN107921136A (cg-RX-API-DMAC7.html)
AU (1) AU2016290197B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018000112A2 (cg-RX-API-DMAC7.html)
CA (1) CA2989522C (cg-RX-API-DMAC7.html)
CL (1) CL2018000057A1 (cg-RX-API-DMAC7.html)
ES (1) ES2835274T3 (cg-RX-API-DMAC7.html)
HK (1) HK1247120A1 (cg-RX-API-DMAC7.html)
IL (2) IL256770B (cg-RX-API-DMAC7.html)
MA (2) MA42016A1 (cg-RX-API-DMAC7.html)
MX (1) MX385229B (cg-RX-API-DMAC7.html)
MY (1) MY187552A (cg-RX-API-DMAC7.html)
PL (1) PL3319639T3 (cg-RX-API-DMAC7.html)
RU (1) RU2018103940A (cg-RX-API-DMAC7.html)
TN (1) TN2017000538A1 (cg-RX-API-DMAC7.html)
UA (1) UA123728C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017006272A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708601B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165218A1 (en) 2017-03-09 2018-09-13 Allysta Pharmaceuticals, Inc Peptides for dry eye disease
CN110996904A (zh) * 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
KR20220054598A (ko) * 2019-07-26 2022-05-03 알레그로 파마슈티칼스, 엘엘씨 비삼출성 황반변성 및 기타 안질환 치료용 펩티드
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4232458A4 (en) * 2020-10-21 2024-10-02 Azura Ophthalmics Ltd COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
SI1881823T1 (sl) * 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Also Published As

Publication number Publication date
MA42016A1 (fr) 2018-03-30
KR102440162B1 (ko) 2022-09-02
KR20180041122A (ko) 2018-04-23
US20200405703A1 (en) 2020-12-31
US20200000786A1 (en) 2020-01-02
MA44935A1 (fr) 2019-08-30
MY187552A (en) 2021-09-29
PL3319639T3 (pl) 2021-03-08
IL256770A (en) 2018-03-29
HK1247120A1 (zh) 2018-09-21
AU2016290197A1 (en) 2018-01-04
MX385229B (es) 2025-03-14
ZA201708601B (en) 2019-05-29
JP2020121985A (ja) 2020-08-13
US10751334B2 (en) 2020-08-25
UA123728C2 (uk) 2021-05-26
MX2017017163A (es) 2018-08-09
US20180200240A1 (en) 2018-07-19
CA2989522A1 (en) 2017-01-12
CA2989522C (en) 2022-10-18
KR20220062688A (ko) 2022-05-17
IL256770B (en) 2021-02-28
TN2017000538A1 (en) 2019-04-12
EP3319639A1 (en) 2018-05-16
JP6752276B2 (ja) 2020-09-09
RU2018103940A (ru) 2019-08-08
CN107921136A (zh) 2018-04-17
IL280827A (en) 2021-04-29
BR112018000112A2 (pt) 2018-09-04
ES2835274T3 (es) 2021-06-22
AU2016290197B2 (en) 2021-07-22
WO2017006272A1 (en) 2017-01-12
RU2018103940A3 (cg-RX-API-DMAC7.html) 2019-09-03
JP2018521126A (ja) 2018-08-02
EP3319639B1 (en) 2020-11-18
US10413535B2 (en) 2019-09-17

Similar Documents

Publication Publication Date Title
CY1121071T1 (el) Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX2017002670A (es) Inhibidores de glucosidasa.
CL2015000942A1 (es) Compuestos de benceno sustituido.
AR094204A1 (es) Composiciones para el cuidado oral que contienen haluros de acido amino
EA201400838A1 (ru) ЗАМЕЩЕННЫЕ АМИДИНОМ β-ЛАКТАМЫ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ СРЕДСТВ
UA122520C2 (uk) Кристалічна форма 2-[4-(4-хлорфенокси)-2-(трифторметил)феніл]-1-(1,2,4-триазол-1-іл)пропан-2-олу, агрохімічна композиція, застосування та спосіб боротьби зі шкідливими грибами
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2014000630A1 (es) Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc.
PE20150200A1 (es) Formulacion de anticuerpos
CL2013003472A1 (es) Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras.
UY34161A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2016001266A1 (es) Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo.
MX2016001480A (es) Formulacion de inhibidores de syk.
CR20140263A (es) Composicion herbicida que contiene acido de 4-amino-3-cloro-6-(-4-cloro-2-fluor-3-metoxifenil) piridina-2-carboxilico, o los derivados del mismo y fluroxipir, o los derivados del mismo
MX2017002967A (es) Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo.
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
CO2018004573A2 (es) Derivados de fenilo como agonistas del receptor 2 de cannabinoides
MX393092B (es) Bis-compuestos para dispositivos opticamente activos.
CL2013000488A1 (es) Co-cristales de compuestos derivados de (2r)-5-oxo-1-(bencilpiperidin-4-il)-n-(piridin-2-il)pirrolidin-2-carboxamida y un agente de formacion de co-cristales; sales de los compuestos; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias e infecciosas.